New details on how a viral protein puts the brakes on virus replication

February 07, 2020

An interdisciplinary team of researchers at Colorado State University has used computational chemistry, biochemistry and virology to uncover new information on how viruses such as West Nile, dengue and Zika replicate. Based on their research, the team said these viruses appear to cripple their own genome replication machinery.

CSU researchers described the results as "surprising," and said the findings have implications for future vaccine and antiviral drug development.

The study, "Motif V regulates energy transduction between the flavivirus NS3 ATPase and RNA-binding cleft," was published in the Journal of Biological Chemistry on Feb. 7.

How a virus replicates

Kelly Du Pont, first author of the study and a doctoral candidate in chemistry at CSU, studies Nonstructural Protein 3 - or NS3 - in flaviviruses, which cause a number of diseases in humans. NS3 is a key enzyme that these viruses use to copy their genomes.

For flaviviruses to replicate, the NS3 helicase - a viral enzyme that binds or remodels nucleic acid - has to unwind the double-stranded ribonucleic acid. NS3 uses adenosine triphosphate or ATP, a molecule abundant in cells, as fuel to power the unwinding.

Du Pont said the unwinding action is similar to what happens with a zipper on a jacket, while the energy produced from ATP driving the unwinding is similar to the transmission system of a car.

"The release of energy from the fuel drives the pistons up and down to turn the transmission and then the wheels, causing the car to move forward," she said. "NS3 uses ATP as its fuel to unwind the double-stranded ribonucleic acid, but we don't know where the crankshaft or transmission is for this machine."

Du Pont said this research was initially focused on trying to figure out what part of the NS3 protein acts as its molecular transmission. While studying the process, the team identified the part of NS3 that acts as a brake during unwinding.

They also identified mutations that make NS3 unwind the double-stranded ribonucleic acid faster than is normally seen, but also make the virus replicate more inefficiently in cells.

Potential for drug, vaccine development

If researchers can learn more about how NS3 unwinds the double-stranded ribonucleic acid and how this process is controlled, they could potentially target areas within the helicase for development of drugs to treat virus-caused diseases.

Brian Geiss, senior author on the study and associate professor of microbiology at CSU, said the findings could also one day lead to improved development of vaccines against these viruses.

"Most vaccines are developed by finding random mutations that slow down virus growth," he said. "By understanding how viral enzymes like NS3 work in great detail, we can use that information to rationally design new mutant viruses that replicate less well and act better as a vaccine, without having to rely on chance to make the vaccine. This can help develop vaccines more rapidly and precisely."

Du Pont, who specializes in creating computational simulations, has been working in Geiss's lab in the Department of Microbiology, Immunology and Pathology. While interdisciplinary work is common at CSU, Geiss said the breadth of Du Pont's project is not typical.

"Kelly represents a true interdisciplinary scientist who can use the tools and knowledge from many different areas of science to answer previously unanswerable questions," he said. "She uses computational chemistry, protein biochemistry and enzymology, and classical virology techniques to study how these viruses work in unprecedented detail. Kelly is what I hope we will see more of in terms of the scientist of the future," he said.

The research team is now taking a closer look at how changes in NS3 affect replication of the virus and how the changes affect the ability of the virus to kill cells. Du Pont and Geiss are also working with the Ebel Laboratory at CSU to see how viruses with altered NS3 proteins infect mosquitoes and alter their survival during infection.
Co-authors on the study include Russell Davidson, a recent graduate of the Department of Chemistry at CSU, and Martin McCullagh, assistant professor in the Department of Chemistry at Oklahoma State University, who conducted this research at CSU.

Colorado State University

Related Vaccine Articles from Brightsurf:

Who should get the COVID-19 vaccine first?
Nineteen global health experts from around the world have proposed a new, three-phase plan for vaccine distribution -- called the Fair Priority Model -- which aims to reduce premature deaths and other irreversible health consequences from COVID-19.

Breakthrough with cancer vaccine
Scientists have developed a new cancer vaccine with the potential to activate the body's immune system to fight a range of cancers, including leukaemia, breast cancer, lung cancer and pancreatic cancers.

How to improve the pneumococcus vaccine
Pneumococcus kills 1 million children annually according to the World Health Organization.

US inroads to better Ebola vaccine
As the world focuses on finding a COVID-19 vaccine, research continues on other potentially catastrophic pandemic diseases, including Ebola and Marburg viruses.

Successful MERS vaccine in mice may hold promise for COVID-19 vaccine
In a new study, published April 7 in mBio, researchers from the University of Iowa and the University of Georgia demonstrate that a new vaccine fully protects mice against a lethal dose of MERS, a close cousin of COVID-19.

Coronavirus Vaccine: Where are we and what's next? (video)
You might have heard that COVID-19 vaccine trials are underway in Seattle.

Why isn't there a vaccine for staph?
A study from Washington University School of Medicine in St.

Exposing vaccine hesitant to real-life pain of diseases makes them more pro-vaccine
New research from Brigham Young University professors finds there is a better way to help increase support for vaccinations: Expose people to the pain and suffering caused by vaccine-preventable diseases instead of trying to combat people with vaccine facts.

Lifetime flu vaccine?
Another year, another flu vaccine because so far scientists haven't managed to make a vaccine that protects against all strains of flu.

On the horizon: An acne vaccine
A new study published in the Journal of Investigative Dermatology reports important steps that have been taken towards the development of an acne vaccine.

Read More: Vaccine News and Vaccine Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to